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Background. Biomarkers to distinguish latent from activeMycobacterium (M.) tuberculosis infection in clinical practice are lacking.
The urinary neopterin/creatinine ratio can quantify the systemic interferon-gamma effect in patients withM. tuberculosis infection.
Methods. In a prospective observational study, urinary neopterin levels were measured by enzyme linked immunosorbent assay
in patients with active tuberculosis, in people with latent M. tuberculosis infection, and in healthy controls and the urinary
neopterin/creatinine ratiowas calculated.Results.We included a total of 44 patients withM. tuberculosis infection and nine controls.
12 patients had active tuberculosis (8 of them culture-confirmed). The median age was 15 years (range 4.5 to 49). Median urinary
neopterin/creatinine ratio in patients with active tuberculosis was 374.1micromol/mol (129.0 to 1072.3), in patients with latentM.
tuberculosis infection it was 142.1 (28.0 to 384.1), and in controls it was 146.0 (40.3 to 200.0), with significantly higher levels in patients
with active tuberculosis (𝑝 < 0.01). The receiver operating characteristics curve had an area under the curve of 0.84 (95% CI 0.70
to 0.97) (𝑝 < 0.01). Conclusions. Urinary neopterin/creatinine ratios are significantly higher in patients with active tuberculosis
compared to patients with latent infection and may be a significant predictor of active tuberculosis in patients withM. tuberculosis
infection.
1. Introduction
A biomarker to discriminate active from latent Mycobac-
terium tuberculosis infection could help in exclusion of occult
pulmonary and extrapulmonary tuberculosis. It could avoid
undertreatment of patients treated as latent tuberculosis on
grounds of a normal chest X-ray which may leave both active
pulmonary and extrapulmonary tuberculosis undetected.
There is no laboratory test available in clinical routine which
can distinguish latent from activeMycobacterium (M.) tuber-
culosis infection. Scientific research so far has identified the
cytokine profile produced by T-lymphocytes as indicator of
active versus latentM. tuberculosis infection [1, 2]. Proteomic
fingerprinting of serum has led to identification of proteins
present in the serum of patients with active tuberculosis
[3]. Application of T-cell phenotyping or proteomic finger-
printing of serum to diagnose active tuberculosis is currently
limited to research settings and may be difficult to translate
into an affordable test usable in clinical routine particularly
in developing countries.
Neopterin in chemical nomenclature 2-amino-4-
hydroxy-6-(D-erythro-1󸀠,2󸀠,3󸀠-trihydroxypropyl)-pteridine
is derived from guanosine triphosphate via the activity of
guanosine triphosphate cyclohydrolase I and is produced by
activatedmonocytes,macrophages, dendritic cells, and endo-
thelial cells and to a lesser extent by renal epithelial cells,
fibroblasts, and vascular smooth muscle cells upon stimula-
tion mainly by interferon-gamma and to a lesser extent by
interferon alpha and beta with its release being enhanced
by tumor necrosis factor [4]. Neopterin is, after production,
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secreted unaltered in urine where it is concentrated. By
calculating urinary neopterin/creatinine ratio, urinary levels
are corrected for variations in urine production resulting
for example from dehydration in a patient who is unwell.
Urinary neopterin levels can be determined by a simple
ELISA system [5] and a dipstick system has been developed
to determine neopterin levels semiquantitatively in serum
[6]. A previous study reported urinary neopterin/creatinine
ratios in patients with active tuberculosis and found them to
be higher than in patients with pneumonia and lung cancer
[7]. Patients with moderately advanced disease had higher
levels than patients with minimal disease.
Neopterin has previously been identified as a candidate
biomarker in tuberculosis, whichmay be suitable as predictor
of treatment effect and relapse [8]. Neopterin levels have not
previously been investigated as amarker distinguishing active
from latentM. tuberculosis infection.
The objectives of this study were to test the hypotheses
that urinary neopterin/creatinine ratio is significantly higher
in patients with active tuberculosis compared to people
with latent M. tuberculosis infection and that urinary neop-
terin/creatinine ratios decrease significantly during treat-
ment of active tuberculosis.
2. Methods
2.1. Study Population. Children and adults diagnosed with
M. tuberculosis infection were recruited prospectively. Active
tuberculosis was diagnosed following the definition by the
guidelines of the National Institute of Health and Care
Excellence of the United Kingdom [9] as patients with
positive tuberculin skin test or positive interferon-gamma
release assay and clinical, radiological, or culture evidence
of tuberculosis. Latent M. tuberculosis infection was defined
following the same guidance as positive tuberculin skin
test and positive interferon-gamma release assay or only
a positive interferon-gamma release assay with no clinical,
radiological, or culture evidence of tuberculosis. Patients with
latentM. tuberculosis infection were recruited after diagnosis
and referral as part of contact investigations around patients
with active pulmonary tuberculosis.
Healthy relatives testing negative by interferon-gamma
release assay and/or tuberculin skin test during contact
screening were recruited as controls. Excluded were patients
with autoimmune disease, on immunosuppressant medica-
tion, or with current infections other than with M. tubercu-
losis or previously completed treatment for M. tuberculosis
infection. The study was performed with ethical approval by
the National Research Ethics Service of the United Kingdom
and local Research and Development Department approval.
Informed written consent was obtained from all patients
and/or legal guardians of children included in the study.
2.2. Sample Collection and Laboratory Analysis. Urine neop-
terin/creatinine levels were measured before start of treat-
ment. Changes of urinary neopterin/creatinine ratios were
investigated during treatment in subgroups of patient with
active and latent M. tuberculosis infection by repeating the
measurement during clinic follow-up after commencement
of treatment. Urinary creatinine levels were determined by
the department of clinical biochemistry of the Luton &
Dunstable University Hospital NHS Foundation Trust.
Urinary neopterin levels were determined by Enzyme
Linked Immunosorbent Assay (ELISA) (IBL Gesellschaft
fuer Immunchemie und Immunbiologie mbH, Hamburg,
Germany) as described previously [5]. Employed was a solid
phase ELISA based on the basic principle of a competitive
ELISA. An unknown amount of antigen in the sample and
a fixed amount of enzyme labelled antigen compete for the
antibody-binding sites (rabbit-anti-neopterin). Both antigen-
antibody complexes bind to the wells of the microtiter strips
coated with a goat-anti-rabbit antibody. Unbound antigen is
removed by washing. The intensity of the colour developed
after the substrate incubation is inversely proportional to the
amount of antigen in the sample. Laboratory analyses were
determined by staff blinded to the status of study participants.
IBL Gesellschaft fuer Immunchemie und Immunbiologie
mbH had no influence on study planning or data analysis or
interpretation.
2.3. Statistical Analysis. Based on a previous study [7], a
sample size calculation was performed. For patients with
active tuberculosis, a urine neopterin/creatinine ratio of
912.6micromol/mol was taken and for patients with latent
M. tuberculosis infection a level of 326.9micromol/mol was
taken, which was the median between patients with minimal
disease and controls in this study and as standard deviation
451.4micromol/mol from the groupwithminimal disease. To
detect a difference between patients with active tuberculosis
and people with latent M. tuberculosis infection with 90%
power at a significance level of 5% based on these figures, it
was determined that at least 9 patients with active tubercu-
losis and 18 people with latent M. tuberculosis infection are
required.
Because of features of a nonparametric distribution,
neopterin/creatinine ratios were compared using the Krus-
kal-Wallis test for multiple comparisons and the Mann-
Whitney 𝑈 test or Wilcoxon signed ranks test (paired sam-
ples) for comparison between two groups. To enable future
sample size calculations, mean and standard deviation for
urinary neopterin/creatinine ratios for patients with active
and latent M. tuberculosis infection were also presented
(see Appendix of Supplementary Material available online
at http://dx.doi.org/10.1155/2016/5643853). Gender in groups
was compared by Chi-square test and Fisher’s exact test.
IBM SPSS version 19.0 was used for statistical analysis. A 𝑝
value of <0.05 was taken to indicate a statistically significant
difference.
3. Results
3.1. Comparison of Urinary Neopterin Levels between Active
and LatentM. tuberculosis Infection. Werecruited 44 patients
with M. tuberculosis infection out of which 12 had active
tuberculosis. Amongst the patients with active tuberculosis, 9
patients had pulmonary and 3 patients had extrapulmonary
tuberculosis (one each with tuberculous lymphadeni-
tis, mandibular tuberculosis, and peritoneal tuberculosis).
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One patient excluded 
because of autoimmune 
disease
Two patients excluded because of 
coinfection (viral respiratory tract, skin
infection); one patient excluded because 
of previous treatment for latent Mycobacterium
tuberculosis infection; one patient excluded 
because of autoimmune skin disease
One patient excluded as on
immunosuppressant treatment 
for ulcerative colitis
12 patients with active tuberculosis
included 
32 patients with latent Mycobacterium
tuberculosis infection included
9 patients without Mycobacterium
tuberculosis infection included
36 patients with latent
Mycobacterium tuberculosis
infection∗∗ approached
10 controls without
Mycobacterium tuberculosis
infection∗∗∗ approached
13 patients with active tuberculosis∗ approached
Figure 1: Flow chart of patient selection. ∗Patients with positive tuberculin skin test or positive interferon-gamma release assay and clinical,
radiological, or culture evidence of tuberculosis. ∗∗Positive tuberculin skin test and positive interferon-gamma release assay or only a positive
interferon-gamma release assay with no clinical, radiological, or culture evidence of tuberculosis. ∗∗∗Healthy relatives testing negative by
interferon-gamma release assay and/or tuberculin skin test during contact screening.
We also recruited nine healthy controls with negative
interferon-gamma release assays on contact screening (for
patient selection flow chart, see Figure 1). In 8/12 patients
(66%), the tuberculosis was confirmed by culture. For patient
characteristics and urinary neopterin/creatinine ratios,
see Table 1. We included Supplementary Table 1 with the
raw data for urinary neopterin levels, urinary creatinine
levels, and urinary neopterin/creatinine ratios. None of
the patients with active tuberculosis has been brought to
our medical attention with a relapse at least two years after
completion of the study and none of the patients with latent
M. tuberculosis infection (LTBI) was diagnosed with active
tuberculosis by our service at least two years after completion
of treatment for latent infection. Age and gender were not
significantly different between groups (𝑝 = 0.43 for age,
female: active tuberculosis versus LTBI 𝑝 = 0.77 and versus
controls 𝑝 = 1.0). Median urinary neopterin/creatinine ratio
was significantly different between groups (𝑝 < 0.01) and
significantly higher in patients with tuberculosis compared
to latent M. tuberculosis infection and controls (𝑝 < 0.01)
and not significantly different between patients with latent
M. tuberculosis infection and controls (𝑝 = 0.66). Figure 2
depicts boxplots of urinary neopterin/creatinine ratios in
patients with tuberculosis and latentM. tuberculosis infection
and healthy controls. To illustrate distribution of ratios in
the groups compared, we included a supplementary figure
with a dot plot (Supplementary Figure 1). To determine
test accuracy in detection of active tuberculosis in all
patients with M. tuberculosis infection, a receiver operating
characteristics curve was generated (see Figure 3).
The receiver operating characteristics curve had an area
under the curve of 0.84 (95% CI 0.70 to 0.97) which was
significantly different (𝑝 < 0.01) from the null hypoth-
esis that there was no discriminatory value of urinary
neopterin/creatinine ratio in detecting active tuberculosis.
3.2. Change of Urinary Neopterin/Creatinine Ratio during
Treatment. In a total of 22 patients with M. tuberculosis
infection, urinary neopterin/creatinine ratios were repeated
at a median of 3 months (interquartile range 3 to 6.8) after
commencement of treatment which consisted in patients
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Table 1
Patients with tuberculosis (𝑛 = 12) Patients with latentMycobacteriumtuberculosis infection (𝑛 = 32)
Healthy controls
(𝑛 = 9)
Age in years (median (range)) 14.7 (5.8 to 37) 14.7 (4.5 to 49) 24 (9 to 40)
Gender (female) 7 19 6
Manifestations of disease
9 pulmonary tuberculosis, 3
extrapulmonary tuberculosis (1 each
lymphadenitis, mandibular, and
peritoneal)
No disease manifestations No diseasemanifestations
Isolation ofMycobacterium
tuberculosis
6/9 patients with pulmonary
tuberculosis, and one each with
tuberculous lymphadenitis, and
mandibular tuberculosis
N/A N/A
Urinary neopterin/creatinine
ratio (micromole/mol, median
(range))
374.1 (129.0 to 1072.3) 142.1 (28.0 to 384.1) 146.0 (40.3 to 200.0)
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Figure 2: Boxplots with median (thick line within the box),
interquartile range (box limits), and extremes (whiskers) of urinary
neopterin/creatinine ratios in patients with active tuberculosis and
latentM. tuberculosis infection and controls.
with active tuberculosis initially of a combination of isoni-
azid, rifampicin, pyrazinamide, and ethambutol for 2 months
followed by 4 months of isoniazid and rifampicin and in
patients with latentM. tuberculosis infection of isoniazid and
rifampicin for 3months. In six patients with active tuberculo-
sis, urinary neopterin/creatinine ratio had a median (range)
of 374.1micromol/mol (174.3 to 1072.3) before treatment and
a median of 200.2 (132 to 440.7) after commencement (𝑝 =
0.17). In the 16 patients with latentM. tuberculosis infection,
median (range) urinary neopterin/creatinine ratio before
treatment 211.95micromol/mol (78.4 to 384.1) and during
treatment 182 (67.2 to 420.8) (𝑝 = 0.87).
4. Discussion
The study presented is the first comparing urinary neop-
terin/creatinine ratios between patients with active and latent
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Figure 3: Receiver operating characteristics (ROC) curve depict-
ing the relationship between sensitivity and specificity of urinary
neopterin/creatinine ratios in detecting active tuberculosis.
M. tuberculosis infection. It is to our knowledge also the
first study investigating neopterin levels in patients with M.
tuberculosis infection using an ELISA. Our study showed that
urinary neopterin/creatinine ratio is a significant predictor of
active tuberculosis in patients withM. tuberculosis infection.
The range of urinary neopterin/creatinine ratios in patients
with active tuberculosis overlapped ratios found in patients
with latent M. tuberculosis infection and controls without
M. tuberculosis infection. This may be due to patients with
active tuberculosis showing suppression of the interferon-
gamma release response by M. tuberculosis by increased
activity of regulatory T-cells [10]. The patient with active
tuberculosis with the lowest urinary neopterin/creatinine
ratio had very limited unilateral axillary lymph node tuber-
culosis (culture positive) without systemic symptoms and
without pulmonary involvement, which illustrates that lim-
ited extrapulmonary tuberculosis may be compatible with
a normal urinary neopterin/creatinine ratio. The difference
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in urinary neopterin/creatinine ratio between active and
latent M. tuberculosis infection found in this study is in
line with previous studies showing a dependency of this
ratio on the extent of tuberculous disease [7, 11]. Urinary
neopterin/creatinine ratios are dependent on age, gender, and
time of day of sampling. There was no difference in age and
gender between groups and urine samples were taken during
amorning clinic in all patients when levels are at their highest
[12]. Previous studies on urinary neopterin/creatinine ratios
in patients withM. tuberculosis infection used High Pressure
Liquid Chromatography (HPLC). This methodological dif-
ferencemakes it difficult to compare the absolute levels found
in previous studies with the levels detected in this study.
Patients of our study with latentM. tuberculosis infection and
controls withoutM. tuberculosis infection had similarmedian
ratios to the mean ratios found by HPLC in healthy people
described previously which ranged, dependent on age, from
101 to 226micromol/mol [9]. Urinary neopterin/creatinine
ratios determined by HPLC in 38 patients with active tuber-
culosis were reported previously [7]. The authors reported
mean and standard deviation despite an apparently skewed
distribution. An estimation of median levels from the scatter
plot of this study points to a median of approximately
500micromol/mol. This median is higher than the median
of 374micromol/mol found in our study.
A high urinary neopterin/creatinine ratio in the absence
of other explanations in a symptomatic patient with nor-
mal chest X-ray should trigger further imaging like chest
computer tomography (CT) and/or abdominal ultrasound
to detect active tuberculosis. Future investigations need
to establish whether, in the context of high infectious
disease burden settings with endemic malaria, HIV, or
helminth infections, which are all associated with elevation
of neopterin levels [4], urinary neopterin/creatinine ratios
remain a useful adjunct in ruling out active tuberculosis in
a patient. As patients with active and latent M. tuberculosis
infection may equally be affected by those background
infections, a different baseline urinary neopterin/creatinine
ratio in patients with latent M. tuberculosis infection may
have to be established. A study conducted in asymptomatic
outpatients in a hospital in Tanzania showed that serum
neopterin levels were elevated above levels found in healthy
people [13]. There is no evidence of an ethnic influence
on neopterin levels as a study in low infectious disease
burden urban populations in Lusaka, Zambia, demonstrated
[14]. We did not find a significant difference in urinary
neopterin/creatinine ratios before and during treatment in
patients with active tuberculosis, which is likely due to the
small sample size for this group. A sample size calculation
showed that to detect a difference with 80% power at a
significance level of 5% at least 16 patients were required.
In patients with latent M. tuberculosis infection, there
was also no difference in neopterin levels before and during
treatment. This may indicate that these patients had either
eliminated the infection before treatment or a low grade
infection is not associated with a significant elevation of
urinary neopterin above the normal level for the individual
patient and healthy controls. The low number of controls
however was not able to exclude a statistically significant
difference. A sample size calculation for design of an obser-
vational study proving equivalence of ratios showed that
52 people are required to exclude with a power of 80% a
difference in means of more than 50micromol/mol [15].
Assessment of accuracy of urinary neopterin/creatinine
ratio in discriminating active from latent M. tuberculosis
infection could be improved and precise cut-offs could be
established by rigorous exclusion of occult pulmonary and
extrapulmonary disease in patients labelled as having latent
M. tuberculosis infection with detailed imaging like CT of the
chest.
Future studies need to investigate urinary neopterin/
creatinine ratios as a noninvasive tool to monitor treatment
success early on and to serve as predictor of treatment failure
and relapse particularly in patients infected with drug resis-
tantM. tuberculosis or in patients infected withM. tuberculo-
sis strains of unknown sensitivity. Clinicians and researchers
hereby need to take into account that immune system
activation involving stimulation of interferon-gamma release
by T-effector cells as in autoimmune diseases like sarcoidosis
or malignancies can increase urinary neopterin/creatinine
ratios [16, 17]. Urinary neopterin/creatinine ratios could, in
low income countries, if measured during treatment of pul-
monary tuberculosis, help triage which patients, if the levels
are not decreasing, requiremore expensive investigations like
drug sensitivity testing and nucleic acid amplification testing.
5. Conclusions
Urinary neopterin/creatinine ratios are significantly higher in
patients with active tuberculosis compared to patients with
latent infection and may be a significant predictor of active
tuberculosis in patients withM. tuberculosis infection.
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